Osimertinib: Revolutionary 5-Year Study Reveals Breakthrough in Lung Cancer Treatment
New Lung Cancer Drug Shown to Have Groundbreaking Impact in 5-Year Study Experts are hailing miraculous results from a clinical trial of Osimertinib, a new medication marketed as Tagrisso. Patients with Stage 1B-3A lung cancer and a specific genetic mutation have seen a reduction in recurrent cancer risk of up to 73% over five years, …